Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration Resistant Prostate Cancer.

Christopher J Sweeney Russell Petry Chang Xu Merrida Childress Jie He David Fabrizio Ole V Gjoerup Samantha Morley Timothy Catlett Zoe June Assaf Kobe Yuen Matthew J Wongchenko Kalpit Shah Pratyush Gupta Priti S Hegde Lincoln W Pasquina Sanjeev Mariathasan Ryon P Graf Thomas Powles

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

In a large cohort of mCRPC patients receiving enzalutamide after abiraterone, we demonstrate the utility of a new tissue-agnostic assay for monitoring molecular response based on ctDNA TF detection and dynamics. CtDNA TF provides a minimally-invasive, complementary biomarker to PSA testing and may refine personalized treatment approaches.

Keyphrases

circulating tumor
prostate cancer
cell free
minimally invasive
circulating tumor cells
squamous cell carcinoma
small cell lung cancer
radical prostatectomy
single molecule
high throughput
replacement therapy
real time pcr